Sentences with phrase «tumor antigens in»

The infection releases tumor antigens in a way that jump - starts the immune response.»

Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P. Somatically mutated tumor antigens in the quest for a more efficacious patient - oriented immunotherapy of cancer.

A team led by principal investigator Donald M. O'Rourke, MD, an associate professor of Neurosurgery at Penn, and Marcela Maus, MD, PhD, showed that CART - EGFRvIII cells had an acceptable safety profile, crossed the blood - brain barrier, infiltrated the tumor, and prompted an immune response, resulting in reduction of the EGFRvIII tumor antigen in GBM cells.

Not exact matches

«To my great surprise, even injecting 10 million activated T cells specific to the P1A antigen did not affect tumor growth in this induced tumor model,» says Van den Eynde.

Prostate cancer risk groups are assigned based on the prostate biopsy results, which include the Gleason score (GS)-- an indication of how aggressively the tumor cells may behave — and the prostate specific antigen (PSA) level in the patient's blood at the time of diagnosis.

She even found evidence that the devils» immune systems were occasionally performing this interferon - gamma trick themselves: In some instances, tumor cells near the edge of the tumor, in close proximity to white blood cells, showed MHC antigens that cells farther within the tumor mass lackeIn some instances, tumor cells near the edge of the tumor, in close proximity to white blood cells, showed MHC antigens that cells farther within the tumor mass lackein close proximity to white blood cells, showed MHC antigens that cells farther within the tumor mass lacked.

Indeed, after Siddle added a squirt of interferon - gamma — a chemical messenger that activates numerous genes involved in producing MHC antigens — to cells cultured from devil tumors, the MHC genes functioned normally again, and the tumor cells» identity cards showed up, plain as day.

Another version, the CTC - iChip, rapidly isolates CTCs in a way that does not rely on preidentified tumor antigens, allowing capture of cells with gene expression patterns that may be missed by the antibodies used in the HBCTC - Chip.

In collaboration with the group of Valerian Kagan, Ph.D., D.Sc., at the University of Pittsburgh, Gabrilovich and colleagues analyzed in great detail the events that take place in the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surfacIn collaboration with the group of Valerian Kagan, Ph.D., D.Sc., at the University of Pittsburgh, Gabrilovich and colleagues analyzed in great detail the events that take place in the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surfacin great detail the events that take place in the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surfacin the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surfacin the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surface.

Different classes of MHC molecules exist and are involved in immunity against pathogens and tumor cells as well as the formation of immune tolerance to self - antigens.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

In this study, we examined the effectiveness of a vaccination targeting tumors that produced IL - 15 and its cell surface receptor called IL - 15R - alpha -LRB--RRB- and examined their ability to up - regulate (or increase) immune responses to tumor antigens,» Morris says.

A relatively new biomarker called prostate - specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

The light - sensitive cells and nanoparticles, called opto - CRAC, were then delivered with the tumor antigen surrogate ovalbumin to mice with melanoma tumors in their lymph nodes to see if an immune response could be activated to target cancer cells.

Mechanistic studies showed that IFN increases antitumor immune responses by enhancing antigen presentation to T cells by dendritic cells present in the tumor microenvironment.

Dr. Gnjatic's research focuses on human antigen - specific immune responses to tumor antigens, in an attempt to define new targets for the development of cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail.

«We had a hunch that rapidly growing tumors can «outgrow» their blood supply, resulting in dead tumor cells that might spill their viral antigens amongst the living cancer cells,» said co-senior study author Arturo Casadevall, chair of Einstein's Microbiology & Immunology department.

«This trial showed that there is a need to target additional antigens in glioblastoma, as well as overcome the immunosuppressive environment that the CAR T cells encountered in the tumor,» Maus said.

Over the past two years, investigators from the Perelman School of Medicine at the University of Pennsylvania have reported results from a human trial in GBM using chimeric antigen receptor (CAR) T cell therapy, through which patients» own T cells were engineered to track down and kill cancer cells that express a tumor - specific protein known as EGFRvIII.

In a 2009 paper published in Nature Materials, Mooney demonstrated that this could be achieved by loading a porous scaffold — about the size of a dime — with tumor antigen as well as a combination of biological and chemical components meant to attract and activate dendritic cellIn a 2009 paper published in Nature Materials, Mooney demonstrated that this could be achieved by loading a porous scaffold — about the size of a dime — with tumor antigen as well as a combination of biological and chemical components meant to attract and activate dendritic cellin Nature Materials, Mooney demonstrated that this could be achieved by loading a porous scaffold — about the size of a dime — with tumor antigen as well as a combination of biological and chemical components meant to attract and activate dendritic cells.

Singlet oxygen tends to rip apart tumor cells in a manner that exposes many new tumor antigens to immune cells called dendritic cells, which, like police executing a dragnet, grab the antigens and present them to T cells for closer inspection.

Researchers now think that irradiation sometimes kills tumor cells in a manner that exposes new antigens to T cells, priming them to target other tumor cells that carry them as well, says Wenbin Lin, a chemist at the University of Chicago in Illinois, and one of the authors of the current study.

In the featured article of The Journal of Nuclear Medicine's October issue, German researchers report on their recent clinical experience, which establishes a dosing regimen for actinium - 225 (225Ac)- labeled targeted alpha therapy of patients with prostate specific membrane antigen (PSMA)- positive tumors.

The types of tumor that can be particularly responsive to immunotherapy generally happen in older people, or people who have genetic factors that allow their tumors to acquire a lot of mutations — so that the tumor has a lot of different antigens that are recognized by the immunotherapy.

Baltimore, Md. (Embargoed until 12:30 pm EDT on Monday, June 8)-- A relatively new biomarker called prostate - specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

[4] Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell - McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S. Phase I trial of overlapping long peptides from a tumor self - antigen and poly - ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

Using transplantable tumor models expressing antigen in an inducible manner or spontaneous tumor models expressing nominal antigens, we try to decipher whether the tumor is ignored or leads to deletion, anergy or class switch of the specific immune response or generate suppressor T cells.

High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.

Monoclonal antibodies are molecules, generated in the lab, that target specific antigens on tumors.

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

Steven A. Rosenberg and colleagues at the Surgery Branch of the National Cancer Institute demonstrate that adoptive immunotherapy with CD8 + T cells genetically engineering to recognize the NY - ESO - 1 antigen could induce significant tumor regressions in patients with metastatic synovial sarcoma and melanoma.

(PMID: 15657293) Download PDF Lurquin C, Lethé B, Corbière V, Théate I, van Baren N, Coulie PG, Boon T. Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Investigating conventional MHC - restricted T cell responses specific for tumor - associated peptide antigens, and local immune contextures, in mediating cancer control in patients following neoadjuvant (per - surgery) therapy.

Specifically, TheraT ® has proven to be safe in animals as well as capable of eliciting uniquely potent antigen - specific CD8 + cytotoxic T cell responses and strong tumor control in mice.

Lloyd Old, Thierry Boon, and colleagues develop the TNF release assay for mouse systems in which release of TNF by T cells could be used to assess specific T cell recognition, facilitating the cloning of human tumor antigens.

While much recent research has not been published in this area, there is actually a long history of studies that show: (1) there is a significant number of antigens shared between tumors and embryonic tissues (called «oncofetal antigens») and, consequently, antibodies made against tumors can also recognize embryonic tissues, and vice versa; (2) pregnancy confers some immunity against cancer (accompanied by antibody production against oncofetal antigens), not only against its occurrence but also against its growth; (3) similar to pregnancy, an immune response against cancer can be generated by vaccinating animals with embryonic tissues.

Phosphorylation of Merkel cell polyomavirus large tumor antigen at serine 816 by ATM kinase induces apoptosis in host cells.

This has involved preclinical and clinical evaluation in Phase I and Phase I / II studies that have characterized tumor antigen expression and immune responses in patients.

These demonstrated that both primary CD4 and CD8 T cell responses and development of memory to protein antigen in adjuvants (e.g. CFA, alum), or to several viruses, or to a range of tumors are strongly controlled by OX40.

Low frequencies of tumor antigen - specific cells in the peripheral blood has been a limiting factor in treatment.

In other words, T - cell destruction of cells bearing mutant spectrin - B2 «sculpted» the tumor cells into poorly immunogenic cells lacking the antigen, which progressed and grew out.

Thus, in a single experiment, the authors demonstrated that (1) CD4 + and CD8 + T - cells were the mediators of immune system rejection of transplanted tumor cells, and (2) d42m1 escape tumors develop from T - cell - dependent selection favoring cells without the spectrin - B2 antigen.

In the next year, members of the Dream Team will continue to study the tumor microenvironment before and after checkpoint blockade, to develop algorithms to identify and predict the best antigens on cancer cells that can be used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of immune cells for adoptive cell therapIn the next year, members of the Dream Team will continue to study the tumor microenvironment before and after checkpoint blockade, to develop algorithms to identify and predict the best antigens on cancer cells that can be used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of immune cells for adoptive cell therapin selecting patients who will benefit, and identifying the best approaches to increase the strength of immune cells for adoptive cell therapy.

Bryan's group has designed a BiTE against the EGFRvIII tumor - specific antigen, which is expressed in a majority of glioblastoma cases, and has performed preclinical tests to determine its efficacy against EGFRvIII - expressing glioblastoma.

She has obtained intramural support through the Vanderbilt Physician Scientist Development (VPSD) Award Program and a Cancer Center Grant Support (CCSG) Award to identify relevant tumor antigens / targets in breast cancer tumor samples.

Our immuno - oncology product candidates are being developed in two separate approaches: one that targets specific antigens and / or epitopes (such as CMB305 and in our neoantigen collaboration); and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization (such as G100).

The difficulty in using monoclonal antibodies against tumor cells is that most of the antibodies raised will be against immunodominant antigens — all the high - visibility proteins that the immune system recognizes.

The specific antigen approach uses selected antigens that are also present in the patient's tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen.

«We are excited to be a part of this important new initiative to develop novel treatment options for patients,» said Ovid Trifan, M.D., Ph.D., chief medical officer of Apexigen, Inc. «APX005M is a potential best - in - class CD40 agonist that works by activating the immune system's antigen - presenting cells in the tumor microenvironment.

Moreover, ablation of a STAT5A allele reduces tumor incidence in a mouse model of breast cancer in which mammary epithelial cells express T antigen (48).